Accelerated Atherosclerosis in Takayasu Disease: Case-Control Study

Hatri, A.; Guermaz, R.; Laroche, J.-P.; Taharboucht, S.; Kessal, F.; Hamrour, F.; Zekri, S.; Mameri, Amel; Brouri, M.

doi:10.4236/ojim.2017.71002

Cited by 2 publications

(1 citation statement)

References 22 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Glutamate, found to be higher in TA patients with higher disease activity, has been previously shown to be associated with inflammation. , Lower LDL/VLDL seen in active TA patients, seems to be in concord with lipid paradox seen in rheumatoid arthritis . It is postulated lower serum cholesterol might result from increased subendothelial deposits and increased catabolism and may thus explain increased CV risk and atherosclerosis in TA patients. − It is interesting to observe the shift in the metabolic profile of inactive TA patients toward normal control (NC) away from active TA as evident from Figure S3. Glucose, NAG, glutamate/proline levels gradually decrease and most of the amino acids, lactate, LDL/VLDL, choline levels increase from active TA to inactive TA to NC.…”

Section: Discussionmentioning

confidence: 83%

NMR-Based Serum Metabolomics of Patients with Takayasu Arteritis: Relationship with Disease Activity

et al. 2018

View full text Add to dashboard Cite

Takayasu arteritis (TA) is a large vessel vasculitis of unknown pathogenesis. Assessment of disease activity is a challenge, and there is an unmet need for relevant biomarker(s). In our previous study, NMR based serum metabolomics had revealed distinctive metabolic signatures in TA patients compared with age/sex matched healthy controls and systemic lupus erythematosus (SLE). In this study we investigate whether the metabolites correlate with disease activity. Patients with TA fulfilling American College of Rheumatology (ACR) criteria were enrolled, and disease activity was assessed using Indian Takayasu Clinical Activity Score using acute phase reactant-erythrocyte sedimentation rate [ITAS-A (ESR)]. Sera were analyzed using 800 MHz NMR spectrometer to identify metabolites [based on partial least squares discriminant analysis (PLS-DA) VIP (variable importance in projection) score > 1.0 and permutation test, p-value <0.01]. 45 active and 53 inactive TA patients with median age 27 [(IQR) 22-35 years] and 27 [(IQR) 23-37 years], female to male ratio 3.5:1 and 4.9:1, and median duration of illness 5 [(IQR) 2-9 years] and 3 [(IQR) 1-6 years], respectively, were enrolled. The key metabolites with highest discriminatory potential in active TA (ITAS-A ≥ 4) were glutamate and N-acetyl glycoprotein (NAG), both elevated, with area under the curve 0.775 and 0.769 ( p-value <0.001). On follow up assessment, metabolic spectra started to differ with change in disease activity. This large cohort of patients revealed metabolic profiles discriminating between clinically active and inactive TA patients. It suggests glutamate and NAG have strong potential as biomarkers for disease activity in TA and may serve as a guide to therapy. We are now working to further validate these results in longitudinal studies.

show abstract